Pitt Shield

Loading Intracranial Drug-Eluting Reservoirs Across the Blood-Brain Barrier With Focused Ultrasound.

Authors: Moody CT, Durham PG, Dayton PA, Brudno Y

Efficient, sustained and long-term delivery of therapeutics to the brain remains an important challenge to treatment of diseases such as brain cancer, stroke and neurodegenerative disease. Focused ultrasound can assist movement of drugs into the brain, but frequent and long-term use has remained impractical. Single-use intracranial drug-eluting depots show promise but are limited for the treatment of chronic diseases as they cannot be refilled non-invasively. Refillable drug-eluting depots could serve as a long-term solution, but refilling is hindered by the blood-brain barrier (BBB), which prevents drug refills from accessing the brain. In this article, we describe how focused ultrasound enables non-invasive loading of intracranial drug depots in mice. Female CD-1 mice (n = 6) were intracranially injected with click-reactive and fluorescent molecules that are capable of anchoring in the brain. After healing, animals were treated with high-intensity focused ultrasound and microbubbles to temporarily increase the permeability of the blood-brain barrier and deliver dibenzocyclooctyne (DBCO)-Cy7. The mice were perfused, and the brains were imaged via ex vivo fluorescence imaging. Fluorescence imaging indicated small molecule refills are captured by intracranial depots as long as 4 wk after administration and are retained for up to 4 wk based on fluorescence imaging. Efficient loading was dependent on both focused ultrasound and the presence of refillable depots in the brain as absence of either prevented intracranial loading. The ability to target and retain small molecules at predetermined intracranial sites with pinpoint accuracy provides opportunities to continuously deliver drugs to the brain over weeks and months without excessive BBB opening and with minimal off-target side effects.

Introduction

Purpose drug delivery with BBB opening
Study Objective Investigate whether focused ultrasound can enable noninvasive loading of intracranial click-chemistry-based drug depots by transiently opening the blood-brain barrier in mice
Animal model / Human subject CD-1 mouse, female, 12-16 weeks
Disease model healthy
MRI or image guidance method Yes (ultrasound imaging, no MRI)
Targeted brain region(s) Striatum
Target coordinates 0 mm anterior, 2 mm lateral, 2.5 mm deep from bregma
Cargo name and characteristics DBCO-Cy7 (fluorescent small molecule, 1,260 Da), click-reactive refill
Route of administration intravenous (tail vein)

Outcomes and Safety

Summary of Outcomes FUS (1 MHz, 0.5 MPa, 1 ms pulses, 100 Hz PRF, 5 min) with microbubbles significantly increased DBCO-Cy7 accumulation in targeted striatum vs non-FUS controls. Combined FUS + intracranial azide depot resulted in highest retention at 4 weeks post-refill. Without FUS, depot alone showed minimal capture; without depot, FUS alone showed some residual fluorescence but less than combination. Colocalization confirmed capture at depot sites.
Duration of biological effect 4 weeks (retention observed at 4 weeks post-refill)

Brain Region

Ultrasound Parameters

Ultrasound instrument SonoVol Vega imaging system with H201 HIFU transducer (Sonic Concepts), focal width 1.5 mm, focal depth 11.81 mm
FUS Frequency 1MHz
FUS Pressure 0.5MPa (peak negative pressure)
FUS Mode pulsed
Pulse duration 1 ms (1000 cycles at 1 MHz)
Duration of a single FUS session 5mins
Focal Characteristics focal width 1.5 mm, focal depth 11.81 mm
Treatment frequency single session (after 4-week healing post-depot implantation)

We are open to feedback. If you see a mistake or have a suggestion, please contact us.

← Back to Search